Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-101556143 Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNJ-101556143 Phase 1 Part 1 - Dose Escalation | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| JNJ-101556143 Phase 1 Part 2 - Formulation Exploration | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| JNJ-101556143 Phase 2 Part 1 - Dose Optimization | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2A - SOAR | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2B - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2C - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2D - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Name | Type | Description |
|---|---|---|
| JNJ-101556143 Formulation 1 | DRUG | Experimental: Oral JNJ-101556143 |
| JNJ-101556143 Formulation 2 | DRUG | Experimental: Oral JNJ-101556143 |
| JNJ-101556143 Formulation 3 | DRUG | Experimental: Oral JNJ-101556143 |
Patients must meet the following criteria to be eligible study participation: Key Inclusion Criteria: All Study Arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D): Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate h...
Top 20 of 53 competitors
JNJ-101556143 Formulation 1 is an investigational small molecule being studied for the treatment of metastatic prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
JNJ-101556143 Formulation 1 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ.
JNJ-101556143 Formulation 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial is currently recruiting participants.
JNJ-101556143 Formulation 1 is being studied in a Phase 1 trial with the identifier NCT06800313. This trial, titled 'Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer,' is recruiting male patients aged 18 years and older in the United States and United Kingdom.
Yes, JNJ-101556143 Formulation 1 is also known as HLD-0915. The clinical trial NCT06800313 refers to the drug as HLD-0915 (JNJ-101556143), indicating that these names are used interchangeably for the same investigational agent.